SCHEMBL4494959

SCHEMBL4494959

CN1CCC(c2ccc(Nc3ncc(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 1/20 0.59
TTK P33981 1/20 0.59
MAP4K1 Q92918 2/20 0.57
PTK2 Q05397 5/20 0.57
SYK P43405 2/20 0.53
FLT4 P35916 2/20 0.50
KDR P35968 2/20 0.50
MAP4K3 Q8IVH8 1/20 0.49
KDM1A O60341 2/20 0.49
MAOA P21397 2/20 0.49
KDM1B Q8NB78 2/20 0.49
RCOR1 Q9UKL0 2/20 0.49
TBK1 Q9UHD2 1/20 0.48
EML4 Q9HC35 1/20 0.48
ALK Q9UM73 1/20 0.48
KIT P10721 1/20 0.48
FLT3 P36888 1/20 0.48
CSF1R P07333 1/20 0.48
JAK3 P52333 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5686231 0.87 SYK (0.50) STAT6TTKMAP4K1PTK2SYK
SCHEMBL30962842 0.83 WEE1 (0.51) STAT6TTKMAP4K1PTK2SYK
SCHEMBL30560067 0.80 MAP4K1 (0.50) STAT6TTKMAP4K1MAP4K3TBK1
SCHEMBL4492001 0.80 SYK (0.62) STAT6TTKPTK2SYKKDR
SCHEMBL17076546 0.80 SYK (0.82) STAT6SYK
SCHEMBL2427453 0.78 HDAC3 (0.57) KDM1AMAOAKDM1BRCOR1EML4
SCHEMBL17005759 0.77 SYK (0.55) MAP4K1PTK2SYK
SCHEMBL19133765 0.76 PARP1 (0.44) JAK3
SCHEMBL5686325 0.76 RAB9A (0.56) SYKJAK3
SCHEMBL4489867 0.75 BRD4 (0.61) STAT6PTK2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504396-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2009-03-17 US disclosed
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
US-20050209221-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-09-22 US disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209221-A1 Substituted heterocyclic compounds and methods of use ICOS, CD4, HLA-DRB1 STAT6 564/4885TTK 3470/4885MAP4K1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.